Leveragen

We are thrilled to share that Leveragen has entered into a multi-target research, option and license agreement with Moderna to advance therapeutic solutions. This collaboration will utilize our unique Singularity Sapiens Mouse, a next-generation genetic model engineered to exclusively produce single-domain antibodies (sdAbs) from the complete human VH repertoire. These fully human sdAbs offer unparalleled diversity, affinity, and developability, making them ideal for developing a wide range of biological modalities. By integrating Leveragen's cutting-edge sdAb technology with Moderna’s pioneering mRNA platform, this partnership aims to create novel treatments targeting diseases with unmet medical needs. We are eager to provide further updates as we move forward in this transformative collaboration. https://lnkd.in/gzykEHRA #Biotech #Leveragen #Moderna #mRNA #SingleDomainAntibodies #Nanobodies #Hcab #VHH #AntibodyTherapeutics

We are excited to announce a strategic collaboration with Moonlight Bio to drive innovation in T cell therapy using fully human single-domain antibodies. This partnership brings together Leveragen’s Singularity Sapiens Mouse platform and Moonlight Bio’s expertise in T cell engineering to develop next-generation therapies for solid tumors—one of the most challenging areas in oncology. By integrating advanced antibody discovery with cutting-edge T cell engineering, this collaboration aims to enhance functionality, persistence, and efficacy in cellular immunotherapies. Leveragen will spearhead the discovery of fully human single-domain antibodies, while Moonlight Bio will lead preclinical development efforts. This partnership underscores Leveragen’s leadership in single-domain antibody discovery and commitment to transforming immunotherapy through groundbreaking science. https://lnkd.in/euwTDngu #Leveragen #MoonlightBio #TCellTherapy #Immunotherapy #SolidTumors #AntibodyDiscovery

We are pleased to announce a strategic partnership with DPBIO, an industry leader in droplet microfluidics technology, to accelerate innovation in antibody drug development. This collaboration integrates DPBIO’s Cytospark? droplet microfluidic single-B cell antibody discovery platform with Leveragen’s Singularity Sapiens Mouse, a next-generation genetic platform for generating fully human single-domain antibodies. DPBIO’s high-throughput Cytospark? platform drastically reduces screening time while maintaining exceptional precision, enabling the rapid identification of functional antibodies. Leveragen’s Singularity Sapiens Mouse produces fully human single-domain antibodies with unparalleled diversity, affinity, and stability, addressing critical challenges in traditional approaches. Together, this partnership aims to deliver transformative technologies, creating innovative solutions for complex therapeutic targets and advancing the development of next-generation biologics to address unmet medical needs. https://lnkd.in/ewY8YA5P #BostonBiotech #MassBio #AntibodyTherapeutics #AntibodyEngineering #TheAntibodySociety

We are pleased to welcome Antibody Solutions as an approved CRO partner for Leveragen’s Singularity Sapiens Mouse platform. This collaboration broadens access to our industry-leading platform, purpose-built to accelerate the discovery of modular, fully human single-domain antibodies for high-impact therapeutic applications. The Singularity Sapiens Mouse platform sets a new benchmark in fully human single-domain antibody discovery, offering high-quality, reliable solutions for biotech and pharma partners driving next-generation therapies. Our collaboration with Antibody Solutions expands the reach of this transformative technology, enabling adaptable and streamlined pathways to therapeutics that meet the stringent standards of modern drug development.

Team Pharma Partnering Summit would like to take this opportunity to express special gratitude to Chris Paschall PhD MBA, of Parallel Bio, Stan Filippine, of Biomedica GMBH, Weisheng Chen of Leveragen, Tom Grammatopoulos, PhD of Axxam, and Siddharth Akolkar of Partex for sharing their knowledge, experience and unique perspective during a panel discussion at Pharma Partnering US Summit 2024 in Boston, MA.

Celebrating Growth & Success! ?? The MBI team had the pleasure of visiting our recent #graduate, Leveragen, at their new location! It’s exciting to see how far they’ve come since their time in our #Startuplab space, and we couldn't be prouder of their continued growth and success. Leveragen’s journey is a testament to the #innovation and hard work that’s driving #CentralMA forward in the #lifesciences. We can’t wait to see what’s next for them! #MBI #Biomanufacturing #StartupSuccess #startup #startuplabsMA #scaleup

Leveragen will be attending Pharma Partnering Summit at Boston this week (October 16-17). Welcome to stop by our booth and join our panel discussion! “Excited to be a panelist at the Pharma Partnering Summit! I look forward to sharing Leveragen’s cutting-edge platform for fully human single-domain antibodies, offering insights into next-gen biologics development, and collaborating with some of the most forward-thinking companies in the industry.” Said Weisheng Chen, Founder and CEO of Leveragen. Leveragen's?Singularity Sapiens Mouse?is a best-in-class platform for developing fully human single-domain antibodies—versatile building blocks for diverse biologics, including multispecifics, ADCs, mRNA, and CAR-T therapies. #BostonBiotech?#MassBio?#AntibodyTherapeutics?#pharmapartneringsummit

We are excited to announce that Leveragen will be the?Lead Partner?for the?15th Annual World Bispecific Summit?in Boston on September 3-5. Our Founder and CEO, Dr. Weisheng Chen, will be presenting?"Singularity Sapiens: A Next-Generation Single-Domain Antibody Mouse Model for Developing Next-Generation Therapeutics"?on September 4 at 10 am. We invite you to visit our booth and attend our poster presentations to learn more about our innovative single-domain antibody platform and licensing opportunities. We look forward to connecting with industry leaders and sharing insights on the future of therapeutic development. #BostonBiotech #MassBio #AntibodyTherapeutics #WorldBispecificForum

We are excited to announce a strategic alliance with @92Bio to develop multi-specific antibodies and other advanced therapeutics using our industry-leading fully human single-domain antibody platform, the Singularity Sapiens Mouse. This collaboration marks a significant milestone in our mission to tackle complex diseases with next-generation solutions. Led by Dr. Ben Buelow, the 92Bio team brings extensive expertise and a proven track record from their successes at Teneobio, including a notable acquisition by Amgen and high-profile partnerships with AbbVie, GSK, J&J, and AstraZeneca. We look forward to the groundbreaking advancements this partnership will bring. Stay tuned for updates! #Biotech #Leveragen #92Bio #AntibodyTherapeutics #SingleDomainAntibodies #Nanobodies #Hcab #VHH #BIO2024? https://lnkd.in/en47xEHH